BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30191523)

  • 1. Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.
    Barata PC; Cooney M; Mendiratta P; Tyler A; Dreicer R; Garcia JA
    Invest New Drugs; 2018 Dec; 36(6):1085-1092. PubMed ID: 30191523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
    Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
    Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
    Lo EN; Beckett LA; Pan CX; Robles D; Suga JM; Sands JM; Lara PN
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):144-8. PubMed ID: 25667107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
    Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
    Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
    Lin GW; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Ma CG; Xiao WJ; Qin XJ
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):520-3. PubMed ID: 22490153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
    Barata P; Cooney M; Tyler A; Wright J; Dreicer R; Garcia JA
    Invest New Drugs; 2018 Jun; 36(3):451-457. PubMed ID: 29476383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
    Nakabayashi M; Oh WK; Jacobus S; Regan MM; Taplin ME; Kantoff PW; Rosenberg JE
    BJU Int; 2010 May; 105(10):1392-6. PubMed ID: 19863532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
    Wong YN; Manola J; Hudes GR; Roth BJ; Moul JW; Barsevick AM; Scher RM; Volk MJ; Vaughn DJ; Williams SD; Fisch MJ; Cella D; Carducci MA; Wilding G
    Clin Genitourin Cancer; 2018 Apr; 16(2):e315-e322. PubMed ID: 29173976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
    Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
    Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
    Gil-Bazo I; Arévalo E; Castillo A; Zudaire ME; Carranza OE; Fusco JP; Castañón E; Collado-Gómez V; López I; Gil-Aldea I
    Clin Genitourin Cancer; 2013 Jun; 11(2):78-84. PubMed ID: 23260990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
    Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
    Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
    Emmenegger U; Booth CM; Berry S; Sridhar SS; Winquist E; Bandali N; Chow A; Lee C; Xu P; Man S; Kerbel RS; Ko YJ
    Oncologist; 2015 Dec; 20(12):1351-2. PubMed ID: 26542984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
    Madan RA; Karzai FH; Ning YM; Adesunloye BA; Huang X; Harold N; Couvillon A; Chun G; Cordes L; Sissung T; Beedie SL; Dawson NA; Theoret MR; McLeod DG; Rosner I; Trepel JB; Lee MJ; Tomita Y; Lee S; Chen C; Steinberg SM; Arlen PM; Gulley JL; Figg WD; Dahut WL
    BJU Int; 2016 Oct; 118(4):590-7. PubMed ID: 26780387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
    Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
    Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
    Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
    Keizman D; Huang P; Carducci MA; Eisenberger MA
    Prostate; 2012 Mar; 72(4):461-7. PubMed ID: 21688281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.